FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316561738> ?p ?o ?g. }

• W2316561738 endingPage "S43" @default.
• W2316561738 startingPage "S35" @default.
• W2316561738 abstract "Allopurinol has been widely used for the treatment of hyperuricemia, however, it may be associated with various adverse effects. Febuxostat has been identified as a potentially safe and efficacious alternative.A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan.The subjects were treated with febuxostat at fixed maintenance doses (20-80 mg/d) or a placebo for 16 weeks. The percentage of patients achieving serum uric acid levels 6.0 mg/dL or less and the percent change in serum uric acid levels after 16 weeks of treatment were evaluated.The percentage of patients achieving serum uric acid levels 6.0 mg/dL or less at 16 weeks was 87.8% in the 80-mg/d dose group, 83.3% in the 60-mg/d group, 82.9% in the 40-mg/d group, 46.5% in the 20-mg/d group, and 2.6% in the placebo group (P < 0.001, Mantel-Haenszel test). A statistically significant dose-response relationship was found. The percent change in serum uric acid levels after 16 weeks of treatment differed significantly between each febuxostat dose group and the placebo group and increased in a dose-dependent manner above 40 mg/d. No deaths, events posing a clinical problem, or serious adverse reactions attributable to febuxostat were noted. Similar results were obtained regardless of gout history.Febuxostat can safely reduce serum uric acid levels to 6.0 mg/dL or less in 80% or more of patients with hyperuricemia (including gout) at doses of 40 mg/d or higher." @default.
• W2316561738 created "2016-06-24" @default.
• W2316561738 creator A5000894813 @default.
• W2316561738 creator A5011340584 @default.
• W2316561738 creator A5016484890 @default.
• W2316561738 creator A5019627435 @default.
• W2316561738 creator A5036936057 @default.
• W2316561738 creator A5047847141 @default.
• W2316561738 creator A5063192431 @default.
• W2316561738 creator A5086129270 @default.
• W2316561738 creator A5086503985 @default.
• W2316561738 creator A5088773176 @default.
• W2316561738 date "2011-06-01" @default.
• W2316561738 modified "2023-09-23" @default.
• W2316561738 title "Placebo-Controlled Double-Blind Dose-Response Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia (Including Gout Patients) in Japan" @default.
• W2316561738 cites W1534146221 @default.
• W2316561738 cites W1948619662 @default.
• W2316561738 cites W1972183313 @default.
• W2316561738 cites W1986095500 @default.
• W2316561738 cites W1993419780 @default.
• W2316561738 cites W2003407110 @default.
• W2316561738 cites W2006726062 @default.
• W2316561738 cites W2013125367 @default.
• W2316561738 cites W2024243897 @default.
• W2316561738 cites W2073496185 @default.
• W2316561738 cites W2076691130 @default.
• W2316561738 cites W2086544233 @default.
• W2316561738 cites W2090874502 @default.
• W2316561738 cites W2098144815 @default.
• W2316561738 cites W2126616478 @default.
• W2316561738 doi "https://doi.org/10.1097/rhu.0b013e31821d351d" @default.
• W2316561738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21654268" @default.
• W2316561738 hasPublicationYear "2011" @default.
• W2316561738 type Work @default.
• W2316561738 sameAs 2316561738 @default.
• W2316561738 citedByCount "24" @default.
• W2316561738 countsByYear W23165617382012 @default.
• W2316561738 countsByYear W23165617382013 @default.
• W2316561738 countsByYear W23165617382014 @default.
• W2316561738 countsByYear W23165617382015 @default.
• W2316561738 countsByYear W23165617382016 @default.
• W2316561738 countsByYear W23165617382017 @default.
• W2316561738 countsByYear W23165617382018 @default.
• W2316561738 countsByYear W23165617382019 @default.
• W2316561738 countsByYear W23165617382020 @default.
• W2316561738 countsByYear W23165617382021 @default.
• W2316561738 countsByYear W23165617382022 @default.
• W2316561738 countsByYear W23165617382023 @default.
• W2316561738 crossrefType "journal-article" @default.
• W2316561738 hasAuthorship W2316561738A5000894813 @default.
• W2316561738 hasAuthorship W2316561738A5011340584 @default.
• W2316561738 hasAuthorship W2316561738A5016484890 @default.
• W2316561738 hasAuthorship W2316561738A5019627435 @default.
• W2316561738 hasAuthorship W2316561738A5036936057 @default.
• W2316561738 hasAuthorship W2316561738A5047847141 @default.
• W2316561738 hasAuthorship W2316561738A5063192431 @default.
• W2316561738 hasAuthorship W2316561738A5086129270 @default.
• W2316561738 hasAuthorship W2316561738A5086503985 @default.
• W2316561738 hasAuthorship W2316561738A5088773176 @default.
• W2316561738 hasConcept C126322002 @default.
• W2316561738 hasConcept C142724271 @default.
• W2316561738 hasConcept C181199279 @default.
• W2316561738 hasConcept C185592680 @default.
• W2316561738 hasConcept C197934379 @default.
• W2316561738 hasConcept C204787440 @default.
• W2316561738 hasConcept C27081682 @default.
• W2316561738 hasConcept C2777820942 @default.
• W2316561738 hasConcept C2778102346 @default.
• W2316561738 hasConcept C2779721657 @default.
• W2316561738 hasConcept C2779881121 @default.
• W2316561738 hasConcept C2780261098 @default.
• W2316561738 hasConcept C2780402116 @default.
• W2316561738 hasConcept C2780932893 @default.
• W2316561738 hasConcept C55493867 @default.
• W2316561738 hasConcept C71924100 @default.
• W2316561738 hasConcept C90924648 @default.
• W2316561738 hasConcept C98274493 @default.
• W2316561738 hasConceptScore W2316561738C126322002 @default.
• W2316561738 hasConceptScore W2316561738C142724271 @default.
• W2316561738 hasConceptScore W2316561738C181199279 @default.
• W2316561738 hasConceptScore W2316561738C185592680 @default.
• W2316561738 hasConceptScore W2316561738C197934379 @default.
• W2316561738 hasConceptScore W2316561738C204787440 @default.
• W2316561738 hasConceptScore W2316561738C27081682 @default.
• W2316561738 hasConceptScore W2316561738C2777820942 @default.
• W2316561738 hasConceptScore W2316561738C2778102346 @default.
• W2316561738 hasConceptScore W2316561738C2779721657 @default.
• W2316561738 hasConceptScore W2316561738C2779881121 @default.
• W2316561738 hasConceptScore W2316561738C2780261098 @default.
• W2316561738 hasConceptScore W2316561738C2780402116 @default.
• W2316561738 hasConceptScore W2316561738C2780932893 @default.
• W2316561738 hasConceptScore W2316561738C55493867 @default.
• W2316561738 hasConceptScore W2316561738C71924100 @default.
• W2316561738 hasConceptScore W2316561738C90924648 @default.
• W2316561738 hasConceptScore W2316561738C98274493 @default.
• W2316561738 hasIssue "4" @default.
• W2316561738 hasLocation W23165617381 @default.
• W2316561738 hasLocation W23165617382 @default.

• next